Article
Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Dec 2010
Wolpin Brian M, Kraft Peter, Xu Mousheng, Steplowski Emily, Olsson Martin L, Arslan Alan A, Bueno-de-Mesquita H Bas, Gross Myron, Helzlsouer Kathy, Jacobs Eric J, LaCroix Andrea, Petersen Gloria, Stolzenberg-Solomon Rachael Z, Zheng Wei, Albanes Demetrius, Allen Naomi E, Amundadottir Laufey, Austin Melissa A, Boutron-Ruault Marie-Christine, Buring Julie E, Canzian Federico, Chanock Stephen J, Gaziano J Michael, Giovannucci Edward L, Hallmans Göran, Hankinson Susan E, Hoover Robert N, Hunter David J, Hutchinson Amy, Jacobs Kevin B, Kooperberg Charles, Mendelsohn Julie B, Michaud Dominique S, Overvad Kim, Patel Alpa V, Sanchéz Maria-José, Sansbury Leah, Shu Xiao-Ou, Slimani Nadia, Tobias Geoffrey S, Trichopoulos Dimitrios, Vineis Paolo, Visvanathan Kala, Virtamo Jarmo, Wactawski-Wende Jean, Watters Joanne, Yu Kai, Zeleniuch-Jacquotte Anne, Hartge Patricia, Fuchs Charles S
Abstract excerpt
BACKGROUND: Subjects with non-O ABO blood group alleles have increased risk of pancreatic cancer. Glycosyltransferase activity is greater for the A(1) versus A(2) variant, whereas O01 and O02 variants are nonfunctioning. We hypothesized: 1) A(1) allele would confer greater risk than A(2) allele, 2) protective effect of the O allele would be equivalent for O01 and O02 variants, 3) secretor phenotype would modify...
Read the complete abstract on PubMed